Gastroesophageal reflux disease
Conditions
Interventions
Vonoprazan(Takecab)20mg once a day in the mornimg.
Esomeprazole(Nexium)20mg once a day in the mornimg.
Sponsors
Kitasato University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients whose chief complain are heartburn or acetic acid more than 2days in a week. 2.Patients who are at least 20 years of age. 3.Patients whose main organs work. 4.Patients who have given written consent to participate in the study.
Exclusion criteria
Exclusion criteria: 1.Patients with a history of hypersensitivity to components of Vonoprazan and Esomeprazole. 2.Patients taking PPI including Vonoprazan and Esomeprazole. 3.Patients taking Atazanavir sulfate and Rilpivirine hydrochloride. 4.Patients who are diagnosed Zollinger-Ellison syndrome and Pernicious anemia. 5.Patients who have complicated other severe diseases and whose clinical trials can not be safety performed or whose effect judgment is difficult. 6.Patients with malignant tumor complications. 7.Patients with a history of surgery of the upper gastrointestinal tract including the stomach and esophagus. 8.Patients who may be pregnant or pregnant. 9.Patients who judged by physician inappropriate to participate in clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time(days) to GERD symptom relief. | — |
Countries
Japan
Contacts
Public ContactKengi Ishido
Kitasato University Internal gastroenterology
Outcome results
None listed